Hyperlipidemia

Metabolism of Human Diseases: Organ Physiology and Pathophysiology

Volumn , Issue , 2014, Pages 295-302

  Durrington, Paul ^a   Soran, Handrean ^a,b  

^a School of Biomedicine   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956800254     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-0715-7_43     Document Type: Chapter

References (15)

1. Durrington PN (2003) Seminar: dyslipidaemia. Lancet 362:717-731
2. Durrington PN (2007) Hyperlipidaemia. Diagnosis and management, 3rd edn. Hodder Arnold, London
3. Critchley J, Liu J, Zhao D, Wei W, Capewell S (2004) Explaining the increase in coronary heart disease in Beijing between 1984 and 1999. Circulation 110: 1236-1244
4. Patel JV, Vyas A, Cruickshank JK, Prabhakaran D, Hughes E, Reddy KS, Mackness MI, Bhatnagar D, Durrington PN (2006) Impact of migration on coronary heart disease risk factors: comparison of Gujeratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis 185: 297-306
5. Rall SC, Mahley RW (2000) Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apoli-poprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) Metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 2835-2862, Chapter 119
6. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125: 1905-1919
7. Asselbergs FW et al (2012) Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 91:823-838
8. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78:410-422
9. Brown MS, Hobbs HH, Goldstein JL (2000) Familial hypercholesterolemia. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) Metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 2863-2913, Chapter 120
10. National Institute for Health and Clinical Excellence (2008) Identification and management of familial hypercholesterolaemia. NICE Guideline 71. www. nice.org.uk/nicemedia/pdf/CG071NICEGuideline. pdf
11. Brunzell JD, Deeb SS (2000) Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In: Scriver CR, Beaudet al, Sly WS, Valle D (eds) Metabolic and molecular bases of inherited disease, 7th edn. McGraw-Hill, New York, pp 2789-2816, Chapter 117
12. Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program, ATP III Update (2004) Implications of recent clinical trials for the ATP III guidelines. http://www.nhlbi.nih.gov/guide-lines/cholesterol/atp3upd04.htm
13. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D (2011) ESC/EAS guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769-1818
14. Charlton-Menys V, Durrington PN (2008) Human cholesterol metabolism and therapeutic molecules. Exp Physiol 93:27-42
15. Cholesterol Treatment Trialists’ (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581-590